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Aim Many hypertensive subjects travel to high altitudes, but little is known on ambulatory blood pressure (ABP) changes and
antihypertensive drugs’ efficacy under acute and prolonged exposure to hypobaric hypoxia. In particular, the efficacy of
angiotensin receptor blockers in this condition is unknown. This may be clinically relevant considering that renin–angio-
tensin system activity changes at altitude. The HIGHCARE-HIMALAYA study assessed changes in 24 h ABP under acute
and prolonged exposure to increasing altitude and blood pressure-lowering efficacy and safety of an angiotensin receptor
blockade in this setting.
Methods
and results
Forty-seven healthy, normotensive lowlanders were randomized to telmisartan 80 mg or placebo in a double-blind, par-
allel group trial. Conventional and AmbulatoryBPs weremeasured atbaseline andon treatment: after8 weeksat sea level,
and under acute exposure to 3400 and 5400 m altitude, the latter upon arrival and after 12 days (Mt. Everest base camp).
Blood samples were collected for plasma catecholamines, renin, angiotensin, and aldosterone. In both groups, exposure
to increasing altitude was associated with: (i) significant progressive increases in conventional and 24 h blood pressure,
persisting throughout the exposure to 5400 m; (ii) increased plasma noradrenaline and suppressed renin–angiotensin–
aldosterone system. Telmisartan lowered 24 h ABP at the sea level and at 3400 m (between-group difference 4.0 mmHg,
95% CI: 2.2–9.5 mmHg), but not at 5400 m.
Conclusion Ambulatory blood pressure increases progressively with increasing altitude, remaining elevated after 3 weeks. An angio-
tensin receptor blockade maintains blood pressure-lowering efficacy at 3400 m but not at 5400 m.
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In spite of the large number of high-altitude studies,1– 4 data on
altitude-related changes in arterial blood pressure (BP) are limited
and somewhat contradictory.2,3 Most available studies indicate that
when measured with the conventional technique BP increases in re-
sponse to acute high-altitude exposure.1 –3,5– 12 However, only
scanty information is available on altitude-induced changes in ambu-
latory blood pressure (ABP),9– 12 which provides a more sensitive es-
timate of the pressor effect of environmental factors and treatment.
Furthermore, the effects of different altitudes on day–night BP pro-
files have never been systematically explored. Finally, little is known
on the safety of antihypertensive drugs and on their effect on conven-
tional BPor ABP in subjects exposed to progressively severe hypoba-
ric hypoxia.9,11,13
Because a large number of individuals, many of whom are affected by
hypertension,14 are temporarily exposed to high altitude, we thought it
wasof interest to determine (i) the changes in conventional BPand ABP
when moving from the sea level to progressively greater altitudes and
(ii) whether the efficacy of antihypertensive treatment in lowering con-
ventional BP and ABP is maintained in these conditions. The latter was
done by administering an angiotensin receptor blocker because this
class ofBP-lowering drugs is largely used in the hypertensive population
and because the activity of the renin–angiotensin system is modified at
high altitude.15 These issues were investigated in the frame of the HIGH
altitude CArdiovascular REsearch (HIGHCARE)-HIMALAYA study in
the Mt. Everest area.
Methods
HIGHCARE-HIMALAYA was a parallel group, randomized, double-
blind, trial comparing the 24 h BP effects of telmisartan 80 mg daily, and
placebo at different altitudes.
Participants
The study included volunteers aged ,65 years, and in good health con-
ditions. Fifty eligible subjects were identified, of whom three withdrew
their consent before the study start. Thus, 47 volunteers (32 males and
15 females) were included. Exclusion criteria were a history of cardiovas-
cular disease or of arterial hypertension, a BP ≥140/90 mmHg at
repeated measurements, any chronic cardiovascular therapy, living at
an altitude .500 m or repeated exposure to altitudes .3000 m
above sea level in the preceding 8 months, a history of severe mountain
sickness or angioedema, pregnancy, or lack of use of effective contracep-
tive methods in women in the fertile age range. All subjects underwent a
comprehensive medical examination before the expedition, and gave
written informed consent to participate. The protocol was approved
by the Ethics Committee of Istituto Auxologico Italiano and the study
was conducted in agreement with Declaration of Helsinki principles.
The study was registered prior to the study start in EU Clinical
Trials Register (www.clinicaltrialsregister.eu) with EudraCT number
2008-000540-14.
Study procedures
Subjects enrolled in the study were stratified by age and sex and rando-
mized in blocks of four to receive either telmisartan 80 mg or placebo
once daily in the morning in the 1:1 ratio. The study drugs were distribu-
ted as identical capsules containing telmisartan 40 mg or placebo. Ran-
domization and distribution of drug containers were done by two
persons not otherwise involved in the study and the randomization list
has not been disclosed to any of the participants or research team
members throughout the study. Subjects started treatment with one
morning capsule of telmisartan 40 mg or placebo, moving to two
morning capsules or the corresponding placebo after 2 weeks in the
absence of adverse effects or marked abnormalities in serum potassium,
plasma creatinine, or sitting BP. After 8 weeks of treatment, participants
travelled by air from Milan, Italy (altitude 120 m) to Kathmandu, Nepal
(1355 m) where they stayed for 3 days. They were then brought by air
to Namche Bazaar (3400 m), where they stayed for another 3 days.
From there they hiked over 5 days to the Mt. Everest south base camp
(5400 m) where they remained for 12 days before returning to Milan in
a 6 day-time. During the sojourn at 3400 and at 5400 m, subjects were
not allowed to perform any further ascent or strenuous physical activity.
Data collection at the Mt. Everest base camp was performed in tents
under conditions of comfortable temperature, while at Namche Bazaar
it was performed in a heated lodge. Participants were asked to take the
study drugs until completion of all measurements (see below) after
return to the sea level. No other drug was allowed during the expedition,
including pharmacological prevention of acute mountain sickness (AMS).
When necessary, however, subjects received medical treatment for this
condition, never lasting .3 days.
Measurements
Conventional BP (two measurements taken 1–2 min apart) and heart
rate (HR) were obtained by a validated oscillometric device (Microlife
A100plus, Microlife, Windau, Switzerland) in the morning hours with
the subject resting in the sitting position for 5 min. 24 h ABP monitoring
was performed by validated oscillometric devices (Spacelabs 90207 and
90217, Spacelabs Healthcare, Issaquah, WA, USA), the device cuff being
applied to the non-dominant arm in the morning and removed after 24 h.
Subjects were instructed to remain still during each measurement and to
attend the scheduled daily activities while avoiding major physical efforts
during the recording. Measurements were programmed every 15 min
during day-time (7–23 h) and every 20 min at night (23–7 h). Mean
values were computed for systolic (S) BP, diastolic (D) BP, and HR over
the 24 h, day- and night-time as defined by subject’s diary. Nocturnal
BP fall was calculated as per cent reduction of night BP vs. the day-time
value. Only recordings with at least 70% of the expected readings rated
as valid by pre-defined criteria16 were considered. Transcutaneous
oxygen saturation (SpO2) was measured with pulse oximeter (Life
Scope, Nihon Kohden, Tokyo, Japan). Plasma noradrenaline and adren-
aline (high-performance liquid chromatography), renin (LIAISON
Direct Renin CLIA, DiaSorin, Italy), serum angiotensin (RIA, Buhlmann
Laboratories, Switzerland), aldosterone (RIA, DiaSorin, Italy), and haem-
atocrit were assessed in a morning blood sample taken after 15 min in a
seated position. All measurements were performed at sea level before
treatment (SLpre), at sea level after 8 weeks on-treatment (SLpost);
during acute (Day 1–3) exposure to the altitude of 3400 m (Namche);
during acute (Day 1–3, BC1) and prolonged (Day 9–12, BC2) exposure
to the altitude of 5400 m and immediately after return to sea level
(SLreturn) (Figure 1). Measurements included also the assessment of
acute mountain sickness symptoms by the Lake Louise Score17 and of
self-reported quality of sleep during the stay at high altitude.
Study variables
The primary variable of interest was 24 h average SBP. Secondary vari-
ables were 24 h DBP and HR; day- and night-time SBP, DBP, and HR; noc-
turnal SBP, DBP, and HR falls and conventional SBP, DBP, and HR values.
Other variables were subjects’ demographic and clinical characteristics,
i.e. age, gender, body mass index (BMI), haematocrit, SpO2, plasma
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noradrenaline and adrenaline, plasma renin, serum angiotensin II, and
aldosterone, self-reported sleep quality. The Lake Louise Score and the
occurrence of adverse events were considered as safety variables.
Sample size
Assuming a standard deviation (SD) of 9 mmHg, we estimated that
20 subjects in each of the two treatment groups were needed to
detect a 6 mmHg difference in 24 h average SBP between the sea level
and the high-altitude condition, with a power of 80% and an alpha of
0.05 in a two-sided t-test.
Statistical analysis
All analyses were performed using R software Version 2.15.3 (R Founda-
tion for Statistical Computing). Continuous variables are reported as
means+ SD or (in adjusted models) as least square means+ standard
error. To assess the effect of the altitude level and the treatment
group, we used the linear mixed-effects models package (nlme, linear,
and non-linear mixed-effects models) accounting for repeated measure-
ments, with a compound symmetry covariance structure fitting the
models by maximizing the restricted log-likelihood. Baseline (SLpre)
values were included as a fixed effect in the linear mixed-effects
models to reduce the error variance by accounting for individual differ-
ences in responses. For multiple post hoc comparisons, we used the algo-
rithm which controls the expected rate of false-positive results for all
positive results (false discovery rate; FDR).18 An a level of 0.05 was
used for all hypothesis tests.
Results
Two of the 47 participants (both in the telmisartan group) were
excluded from analysis because of non-adherence with the study
procedures. Two additional subjects randomized to active treatment
stoppeddrug intake early in the study, but because theycompleted all
study procedures, they were considered as belonging to the placebo
group for data analysis (Figure 2). Their exclusion in a safety analysis
did not change the principal findings of the study. The placebo
(n ¼ 25) and telmisartan (n ¼ 20) groups did not differ for age,
gender distribution (18 males/7 females vs. 13 males/7 females), BMI,
or baseline BP values (Figure 3 and Table 1). The study took place in
the second half of year 2008.
Effects of high altitude on conventional
and ambulatory blood pressure
In the placebo group, exposure to 3400 and 5400 m above sea level
was associated with a progressive increase in either conventional
and ambulatory SBP and DBP, which persisted after prolonged
sojourn at the higher altitude, falling to the initially lower values
when subjects returned to the sea level (Figure 3; Supplementary
material online, Table S1). The ABP increase was greater than the
conventional BP increase and, at the highest altitude reached,
particularly marked during the night-time (Figures 3 and 4) with
thus a reduction in nocturnal dipping (Figure 5). Exposure to the
two high-altitude levels was associated with a progressive and per-
sistent increase in either conventional or ambulatory HR, as well
(Figure 6). The Lake Louise Score was ≥3 (considered as indicative
of AMS) in 9 subjects at Namche, in 22 subjects at CB1, and in 3 sub-
jects atCB2. Therewere no differences in terms of pressor response
to altitude (defined as increase in 24 h, day-time or night-time BP
compared with SLpost) or in terms of nocturnal BP fall size
Figure1 Timeline of the HIGHCARE-HIMALAYA study. For the description of study time points refer to the text. m a.s.l., meters above sea level.
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between subjects with or without AMS. In a sensitivity analysis, BP
increase at altitude of 5400 m was particularly pronounced in sub-
jects aged over 50 years (increase in 24 h SBP at BC1 24.6 vs.
15.2 mmHg in younger subjects; at BC2 22.9 vs. 12.1 mmHg, re-
spectively, P, 0.01 for both), but the overall statistical model of
BP in the study did not change substantially after including age as
covariate.
Effects of angiotensin receptor blockade
on the blood pressure effects of high
altitude
Telmisartan did not have a significant lowering effect on conventional
BP while it caused a significant ABP reduction at sea level and at the
altitude of 3400 m (between-group difference in 24 h systolic BP
4.0 mmHg, 95% CI: 2.2–9.5 mmHg), without preventing the
pressor response to high altitude (Figure 3; Supplementary material
online, Table S1). At 5400 m, however, the BP-lowering effect of
the drug was no longer evident upon arrival (21.1 mmHg, 95% CI:
23.2 to 1.1 mmHg) and after 12 days of permanence at this altitude
(1.9 mmHg, 95% CI:20.5 to 4.4 mmHg) with only some recovery of
treatment effect on night-time DBP and after returning to sea level
(Figures 3 and 4). Telmisartan had no significant effect on HR both
at sea level and at high altitudes (Figure 6).
Other findings
As shown in Figure 7, in the placebo group noradrenaline showed
a marked progressive increase with exposure to the 3400 and
5400 m altitude, with a tendency to return to baseline values upon
return to sea level. No changes in adrenaline levels were observed.
In contrast, renin, angiotensin II, and aldosterone were reduced at
high altitude and the changes were significant (P, 0.05 for all) at
5400 m. Altitude exposure was also associated with a progressive in-
crease in haematocrit (41.1+3.9% at SLpost, 43.9+4.9% atNamche,
50.1+5.5% at BC1, 53.5+5.6% at BC2, and 43.8+4.68 at SLreturn
again with no differences between untreated and treated subjects.
Reducednocturnal BP dipping appeared tobe present only in subjects
with reduced quality of sleep but not in those who reported optimal
quality although the interaction was only significant for SBP at BC2
(Supplementary material online, Figure S1).
Few adverse events were reported during the study. In the
telmisartan group, one subject reported facial oedema after a few
days of treatment, leading to drug suspension. Another subject had
symptomatic hypotension at the base camp, which disappeared
after halving the drug dose.
Therewereno between-group differences at high altitude in either
SpO2 (90.6+2.6 vs. 91.0+2.8% at Namche, 77.7+5.5 vs. 77.5+
5.9% at BC1, 85.9+ 3.3 vs. 85.7+4.3% at BC2, respectively) and in
the Lake Louise Score.
Figure 2 Flow of subjects in the study.
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Figure 3 Conventional, 24 h, day-time and night-time systolic blood pressure and diastolic blood pressure for the different study conditions in
placebo (blue lines) and telmisartan (red lines) treated subjects. Data are separately shown at sea level pre-treatment (SLpre), at sea level post-
treatment (SLpost), at 3400 m (Namche), at the Mt. Everest base camp, 5400 m, during first 3 days (BC1) and after 11–12 days (BC2), and imme-
diately after return to sea level (SLreturn). Different symbols indicate the level of statistical significance between-groups and among different alti-
tudes. Conv, conventional BP values.
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Our paper provides several new observations on the effects of high
altitude on ABP in subjects without and with antihypertensive drug
treatment. These observations will be discussed separately.
Effects of high altitude on ambulatory
blood pressure
In our subjects, exposure to progressively higher altitude was asso-
ciated with a progressive, marked increase of systolic and diastolic
ABP. The increase (i) occurred immediately after the high altitude
was reached; (ii) persisted during prolonged altitude exposure;
(iii) involved the day-time ABP values but was particularly pronounced
for the night-time ones, with a consequent reduction of the nocturnal
dipping phenomenon at the higher altitude; and (iv) disappeared after
return to sea level. Following the somewhat inconsistent results of
the fewstudies that have addressed this issue in the past,9– 12 this pro-
vides solid evidence that high altitude has an acute and persistent,
albeit reversible, pressor effect on daily life BP, with a similarly
acute, persistent, and reversible alteration of its circadian pattern.
High altitude and antihypertensive drug
treatment
Only two previous studies have addressed the effect of antihyperten-
sive drugs on the 24 h ABP values at high altitude, both of them
showing a limited ability of beta-adrenergic receptor blockers to
prevent the BP increase that occurs in this circumstance.9,11 In our
subjects, the BP-lowering effect of telmisartan observed at the sea
level was preserved at an altitude of 3400 m but disappeared when
the altitude of 5400 m was reached. At variance from what observed
with beta-blockers, the administration of which was accompanied by
a lower SpO2 and worse exercise capacity and tolerability,
11,13
administration of telmisartan at high altitude was well tolerated
with no negative impact on SpO2 or AMS severity. This provides
the first demonstration that the efficacy of one of the most
common treatments of hypertension, i.e. that based on a blockade
of angiotensin II receptors, is preserved during acute exposure to
moderate altitudes, but is impaired when subjects move to very
high altitudes. At a practical level this implies that, in subjects
already under angiotensin II receptor blockade, treatment efficacy
will likely be maintained up to 3400 m, that is at altitudes that can
be reached by trekkers, climbers, skiers, or workers, although we
cannot be certain that this extends to some hypertensive subjects
at older age in whom renin–angiotensin system activity is different
already at sea level. In contrast, patients should be warned that the
antihypertensive effect of an angiotensin II receptor blockade will
likely be lost at very high altitudes, at which they will probably
move from a controlled to an uncontrolled BP state.
Mechanisms
Previous studies haveshownthatexposure tohigh altitudes is accom-
panied by sympathetic activation19– 21 due to stimulation of chemor-
eceptors by hypoxia.2 This is likely to be the primary reason for the
pressor response to high altitude seen in our subjects because
plasma noradrenaline (but not adrenaline) levels showed a progres-
sive increase at progressively higher altitude in parallel with both the
ABP increase and the SpO2 reduction in line with previous reports.
9
On the other hand, our results do not support the hypothesis that
BP increase was due to stress related to AMS, as no relationship
was found between BP changes and AMS occurrence. The pressor
effect of high altitude may not just have a single responsible mechan-
ism, however, and factors such as blood viscosity and endothelin-1
levels (both of which have been shown to increase at high alti-
tude)22,23 are also likely to be involved. Our data provide indirect
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics of study participants
Telmisartan, n5 20 Placebo, n 5 25 All, n5 45
Age (years) 40.3+10.8 39.3+9.8 39.7+10.1
Sex (M/F) 13/7 18/7 31/14
BMI (kg/m2) 23.4+2.8 22.2+2.9 22.7+2.9
SBP
24 h (mmHg) 118.7+8.1 117.7+7.8 118.2+7.9
Day-time (mmHg) 122.8+8.3 122.2+8.7 122.5+8.5
Night-time (mmHg) 109.4+10.0 107.2+5.6 108.2+7.9
Nocturnal dip (%) 10.9+5.9 12.1+3.9 11.6+4.9
DBP
24 h (mmHg) 73.8+7.4 73.9+5.4 73.9+6.3
Day-time (mmHg) 77.7+7.4 78.7+5.8 78.3+6.5
Night-time (mmHg) 64.7+8.5 63.4+4.6 64.0+6.6
Nocturnal dip (%) 16.9+6.4 19.2+5.4 18.1+5.9
HR
24 h (mmHg) 63.7+9.2 67.7+8.3 65.9+8.8
Day-time (mmHg) 67.1+9.2 71.4+9.6 69.4+9.6
Night-time (mmHg) 56.1+9.9 59.2+7.3 57.7+8.6
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support to a contribution of blood viscosity because at high-altitude
subjects exhibited an increase in haematocrit. More importantly, they
provide clear evidence that no contribution to the pressor effect
could have come from the renin–angiotensin–aldosterone system,
the activity of which was suppressed at very high altitude (5400 m),
in line with the results of previous studies.24– 26 This suppression pre-
sumably explains the concomitant reduction of the antihypertensive
effect of telmisartan, as supported by a tendency of telmisartan to
partially recover its efficacy after almost 2 weeks of permanence at
5400 m (BC2), in parallel with a partial recovery of the RAAS activity.
Indeed, at BC2 the activity of the renin–angiotensin–aldosterone
system tended to increase again, probably due to adaptation to
hypoxia and to progressive reduction of volaemia, typical of pro-
longed high-altitude permanence. It seems reasonable to speculate
that not only angiotensin receptor antagonists, but also all renin–
angiotensin–aldosterone system antagonists (ACE inhibitors, anti-
aldosterone drugs, and renin inhibitors) are less or not at all effective
at very high altitudes.
The reasons behind the observed reduction in nocturnal dipping at
altitude of 5400 m are less clear. While our data do not fully explain
this phenomenon, we may still propose several plausible mechan-
isms. One, at least during prolonged exposure to high altitude,
poor sleep quality seemed to play an important role. Two, while
we found no direct relationship with sleep breathing disorders, it is
possible that nocturnal SpO2 reduction contributed to the dispro-
portionate increase in nocturnal BP values. In fact SpO2 was lower
during the night than the day, presumably leading to a greater night-
time hypoxic chemoreceptor stimulation.27 Three, baroreflex func-
tion may also be altered at high altitude as reported previously by
some authors.28,29 Such alteration may have affected BP responses
to posture changes and sleep in a similar way as in subjects with
disease-related autonomic dysfunction (e.g. diabetic autonomic
neuropathy and parkinsonism), where a non-dipping pattern is also
common.
In summary, BP increase at high altitude appears to depend
primarily on chemoreflex-induced increase in sympathetic activ-
ity. Other factors, such as increased blood viscosity and
endothelin-1 levels may contribute as well. The observed
more pronounced increase in nocturnal BP at 5400 m could be
due to poor sleep quality, reduced blood oxygenation at night
Figure 4 Averaged 24 h systolic and diastolic blood pressure profiles in both treatment groups. Data are shown separately at sea level post-
treatment (SLpost, green lines), at 3400 m (Namche, yellow lines), at the Mt. Everest base camp, 5400 m, during the first 3 days (BC1, red lines) and
after 11–12 days (BC2, blue lines). Altitude exposure was associated with a progressive upwards shift in 24 h BP profiles, more evident for nocturnal
blood pressure.
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and/or to altered arterial baroreflex function. Renin–angiotensin–
aldosterone system suppression at very high altitude seems
to affect the BP lowering efficacy of the antagonists of this
system.
Strengths and limitations
Our study has a number of strengths, including a sample size larger
than in most available studies at high altitude, a controlled design by
which the effect of antihypertensive treatment was assessed, the
quality of the ABP measurements and data collection at multiple
points, including the one after return to the sea level. There are,
however, also some inevitable limitations. One, although an effort
was made to standardize subjects’ activities, we cannot exclude
that the pressor effect of high altitude on ABP might have been
affected by behavioural modifications. However, we have previously
observed that high-altitude exposure (4500 m above sea level)
increased ABP and reduced night-time dipping also in subjects
confined in an alpine shelter, with behavioural activities that were
kept similar to those at the sea level.11 Furthermore, behavioural
changes were not responsible for the loss of the effect of antihyper-
tensive drug treatment at very high altitude because, based on their
diary, there were no behavioural differences between placebo and
telmisartan-treated patients. Thus, even if potentially involved, the
‘behavioural’ factors cannot entirely explain our findings. Two, for
obvious reasons, our study could only include healthy volunteers in
a good physical shape. While it seems reasonable to extrapolate
the results to hypertensive subjects, direct evidence is needed to
confirm that the pressor response to high altitude and the changes
in the efficacy of antihypertensive treatment occur to a similar
degree also in this group.
Figure5 Changes in the size of nocturnal blood pressure dipping
(reduction of blood pressure at night expressed as percentage of
day-time average) in both treatment groups throughout the study.
For abbreviations and symbols see Figures 2 and 3.
Figure 6 Changes in conventional, 24 h, day-time and night-time heart rate in both treatment groups throughout the study. Data for the placebo
group are shown in blue, while those for the telmisartan group in red. For other abbreviations see Figures 2 and 3.
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A final contribution of our study deserves to be mentioned. In our
subjects, the pressor effect of high altitude was more visible on ABP
than on conventional BP. Furthermore, only ABP showed the antihy-
pertensive effect of telmisartan and its modification above sea level.
This offers another example of the superiority of ABP monitoring
over conventional BP measurements.30 This may be particularly the
case when unusual environmental conditions affecting BP, such as
high altitude, are studied.
Supplementary material
Supplementary material is available at European Heart Journal online.
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